Clovis Oncology Com (CLVS) Position Maintained by Gabelli Securities Inc; Gentex Com (GNTX) Holding Upped by Messner & Smith Theme Value Investment Management Ltd

February 16, 2018 - By Marie Mckinney

Messner & Smith Theme Value Investment Management Ltd increased its stake in Gentex Corp Com (GNTX) by 60.63% based on its latest 2017Q3 regulatory filing with the SEC. Messner & Smith Theme Value Investment Management Ltd bought 38,585 shares as the company’s stock declined 8.68% while stock markets rallied. The institutional investor held 102,228 shares of the o.e.m. company at the end of 2017Q3, valued at $2.02 million, up from 63,643 at the end of the previous reported quarter. Messner & Smith Theme Value Investment Management Ltd who had been investing in Gentex Corp Com for a number of months, seems to be bullish on the $6.51B market cap company. The stock increased 0.70% or $0.16 during the last trading session, reaching $22.94. About 2.25M shares traded. Gentex Corporation (NASDAQ:GNTX) has risen 19.63% since February 16, 2017 and is uptrending. It has outperformed by 2.93% the S&P500.

Gabelli Securities Inc increased its stake in Clovis Oncology Inc Com (CLVS) by 42.03% based on its latest 2017Q3 regulatory filing with the SEC. Gabelli Securities Inc bought 8,700 shares as the company’s stock declined 20.61% while stock markets rallied. The hedge fund held 29,400 shares of the health care company at the end of 2017Q3, valued at $2.42M, up from 20,700 at the end of the previous reported quarter. Gabelli Securities Inc who had been investing in Clovis Oncology Inc Com for a number of months, seems to be bullish on the $2.68 billion market cap company. The stock increased 0.91% or $0.49 during the last trading session, reaching $54.58. About 842,696 shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has risen 282.71% since February 16, 2017 and is uptrending. It has outperformed by 266.01% the S&P500.

Investors sentiment increased to 1.24 in Q3 2017. Its up 0.32, from 0.92 in 2017Q2. It improved, as 35 investors sold GNTX shares while 109 reduced holdings. 41 funds opened positions while 137 raised stakes. 224.48 million shares or 0.88% less from 226.47 million shares in 2017Q2 were reported. Boston Private Wealth Ltd, a Massachusetts-based fund reported 20,000 shares. Ls Inv Advsr Llc holds 0.03% or 25,972 shares in its portfolio. Texas Permanent School Fund owns 208,463 shares. Smithfield Trust stated it has 455 shares. Menta Capital Limited Liability Company holds 0.13% or 45,650 shares in its portfolio. Clearbridge Investments Ltd Liability Company holds 2.67M shares or 0.05% of its portfolio. Arrowstreet Cap Ltd Partnership has invested 0.02% in Gentex Corporation (NASDAQ:GNTX). Advisory Svcs Network Lc reported 0.04% in Gentex Corporation (NASDAQ:GNTX). Ny State Teachers Retirement Sys has 0.02% invested in Gentex Corporation (NASDAQ:GNTX). Rhumbline Advisers invested in 745,276 shares. Georgia-based Zwj Inv Counsel Inc has invested 0.02% in Gentex Corporation (NASDAQ:GNTX). Smith Graham And Communication Investment Advsrs Ltd Partnership holds 0.5% or 241,150 shares in its portfolio. 117,900 were accumulated by Azimuth Capital Mngmt Limited Company. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 22,681 shares. Tiedemann Wealth Mngmt Limited Co stated it has 43,763 shares or 0.04% of all its holdings.

Among 7 analysts covering Gentex Corp (NASDAQ:GNTX), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Gentex Corp had 19 analyst reports since October 20, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, October 12 by KeyBanc Capital Markets. The stock of Gentex Corporation (NASDAQ:GNTX) earned “Neutral” rating by Robert W. Baird on Wednesday, January 27. Robert W. Baird maintained the stock with “Outperform” rating in Monday, October 23 report. On Monday, November 13 the stock rating was maintained by KeyBanc Capital Markets with “Buy”. The firm has “Buy” rating by Robert W. Baird given on Friday, October 20. The stock of Gentex Corporation (NASDAQ:GNTX) has “Hold” rating given on Tuesday, January 23 by Robert W. Baird. The company was initiated on Monday, December 19 by Susquehanna. The stock of Gentex Corporation (NASDAQ:GNTX) earned “Buy” rating by FBR Capital on Tuesday, January 2. The rating was upgraded by Robert W. Baird to “Outperform” on Thursday, August 24. The rating was maintained by KeyBanc Capital Markets with “Buy” on Wednesday, August 23.

Since September 27, 2017, it had 0 insider buys, and 8 selling transactions for $2.88 million activity. The insider Ryan Scott P sold $170,823. Shares for $611,341 were sold by MULDER JOHN A on Monday, January 29. 12,000 shares valued at $280,776 were sold by Wallace James H on Tuesday, January 30. On Monday, January 29 GOODE GARY F sold $280,968 worth of Gentex Corporation (NASDAQ:GNTX) or 12,000 shares. 47,000 shares valued at $1.11M were sold by Hoekstra Peter on Monday, January 29. Downing Steven R also sold $157,582 worth of Gentex Corporation (NASDAQ:GNTX) on Wednesday, September 27.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 14 have Buy rating, 0 Sell and 6 Hold. Therefore 70% are positive. Clovis Oncology had 56 analyst reports since September 10, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, July 18 by Credit Suisse. JP Morgan upgraded the stock to “Overweight” rating in Wednesday, May 17 report. The firm has “Hold” rating by WallachBeth Capital given on Tuesday, November 17. The firm earned “Buy” rating on Tuesday, June 20 by Janney Capital. The firm earned “Buy” rating on Monday, February 5 by Leerink Swann. Bank of America initiated it with “Buy” rating and $74 target in Friday, January 27 report. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) has “Buy” rating given on Thursday, June 1 by J.P. Morgan. Morgan Stanley initiated the shares of CLVS in report on Friday, January 13 with “Overweight” rating. The company was maintained on Monday, January 25 by Mizuho. JP Morgan downgraded Clovis Oncology, Inc. (NASDAQ:CLVS) on Wednesday, April 13 to “Neutral” rating.

Gabelli Securities Inc, which manages about $1.30B and $867.10 million US Long portfolio, decreased its stake in Lennar B Shares by 45,445 shares to 146,357 shares, valued at $6.60M in 2017Q3, according to the filing. It also reduced its holding in Brocade Communications Sys Ico (NASDAQ:BRCD) by 59,432 shares in the quarter, leaving it with 823,016 shares, and cut its stake in Incyte Genomics Inc Com (NASDAQ:INCY).

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>